摘要
背景:20世纪20年代首次考虑使用吖啶作为抗癌剂。此后,大量的吖啶类药物已经作为抗肿瘤剂进行了测试,包括吖啶发色团上含有硫的化合物。在这篇综述中,我们将讨论最近的研究,这些研究调查了这类吖啶衍生物的抗癌活性。 方法:我们将自己长达十年的研究结果以及现有研究文献的结果提交给含硫吖啶衍生物的抗癌活性。这些化合物表现出特定的肿瘤细胞杀伤特性的证据表明使用这种分子作为抗癌治疗剂的可能性。 结果:在过去的十年中,通过修改吖啶核上取代基的位置和性质开发了许多吖啶类似物。在本文中,我们发表了关于含硫吖啶衍生物(吖啶硫脲,吖啶噻唑烷/噻唑烷酮和吖啶缩氨基硫脲/氨基硫脲)的抗癌活性的结果。在癌症化疗中,药物的机理是复杂的,尽管对吖啶的抗癌活性的研究产生了令人兴奋的结果。 结论:在这篇综述中,我们总结了最近有关含硫吖啶衍生物抗癌活性的文献。大量公开的数据表明这些化合物对选定的癌细胞系显示出有希望的抗癌活性。所获得的结果可以有助于新药剂的开发。
关键词: 临床前研究,癌细胞系,吖啶衍生物,硫,硫脲,噻唑烷酮。
Current Medicinal Chemistry
Title:Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Volume: 25 Issue: 17
关键词: 临床前研究,癌细胞系,吖啶衍生物,硫,硫脲,噻唑烷酮。
摘要: Background: The possible use of acridines as anticancer agents was first considered in the 1920´s. Since then, a large number of acridine drugs have been tested as antitumour agents, including compounds containing sulphur on the acridine chromophore. In this review, we will discuss recent studies which have investigated the anticancer activity of this class of acridine derivatives.
Methods: We present the results both of our own decade-long research and also of existing research literature into the anticancer activity of acridine derivatives containing sulphur. The evidence of specific tumor-cell killing properties displayed by these compounds suggest the potential of using such molecules as anticancer therapeutics.
Results: During the last decade, a number of acridine analogs have been developed by modifying the position and the nature of the substituent on the acridine core. In this paper, we published results on the anticancer activity of acridine derivatives containing sulfur (acridine thioureas, acridine thiazolidine/thiazoidinone, and acridine thiosemicarbazones/ thiosemicarbazides). In cancer chemotherapy, the mechanism of the drugs is complex, although the study of the anticancer activity of acridines has yielded exciting results.
Conclusion: In this review we have summarized recent literature on the anticancer activity of acridine derivatives containing sulfur. A considerable amount of published data suggests that these compounds exhibit promising anticancer activity against selected cancer cell lines. The obtained results can be helpful in the development of new pharmaceutical agents.
Export Options
About this article
Cite this article as:
Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines, Current Medicinal Chemistry 2018; 25 (17) . https://dx.doi.org/10.2174/0929867324666170414165019
DOI https://dx.doi.org/10.2174/0929867324666170414165019 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier
Current Gene Therapy Amyloid Precursor Protein Processing in Vivo - Insights from a Chemically- Induced Constitutive Overactivation of Protein Kinase C in Guinea Pig Brain
Current Medicinal Chemistry Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design New Strategy Developments in Brain Tumor Therapy
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cancer Therapy Reviews The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Meet Our Editorial Board Member
Protein & Peptide Letters Ultrasmall Nanoclusters: Synthesis and Applications as an Emerging Platform for Imaging and Therapy
Current Analytical Chemistry Molecular Markers of Glial Tumors: Current Targeting Strategies
Current Medicinal Chemistry Hemichannels in Cerebral Ischemia
Current Molecular Medicine DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Local Gene Delivery for Cancer Therapy
Current Gene Therapy Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets